<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465568</url>
  </required_header>
  <id_info>
    <org_study_id>CREC/984/11</org_study_id>
    <nct_id>NCT01465568</nct_id>
  </id_info>
  <brief_title>Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis</brief_title>
  <official_title>Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the efficacy of denosumab, a new drug, in the treatment
      of osteoporosis in patients using bisphosphonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no data on the use of denosumab in steroid induced osteoporosis. Postmenopausal
      women with chronic use of Glucocorticoid (GCs) are at high-risk of osteoporotic fractures.
      Despite bisphosphonate treatment, a certain proportion of high-risk patients using chronic
      GCs either do not achieve a satisfactory gain in bone mineral density (BMD) or develop new
      fragility fractures. Thus, more potent osteoporosis treatment is necessary for this subgroup
      of patients. This prompts the current study which aims to examine the efficacy of denosumab
      in current users of oral bisphosphonates for Glucocorticoid-induced Osteoporosis (GIOP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density (BMD) changes at the lumbar spine</measure>
    <time_frame>baseline, 6 months and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMD changes in the total hip and femoral neck</measure>
    <time_frame>baseline, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone turnover markers</measure>
    <time_frame>baseline, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New vertebral fractures</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bisphosphonates</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuation of bisphosphonates</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>60mg subcutaneous injection 6 monthly for 2 doses</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisphosphonates</intervention_name>
    <description>continue present bisphosphonate treatment</description>
    <arm_group_label>bisphosphonates</arm_group_label>
    <other_name>continuation of bisphosphonates in their usual dosages</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women or adult men (&gt;18 years of age) with various medical diseases requiring
             long-term prednisolone treatment. Pre-menopausal women should have no plan for
             pregnancy within 2 years of study entry and agree to practice contraception during
             this 2-year period.

          2. A daily dose of prednisolone (or equivalent) of more than 2.5mg within 3 months of
             study entry.

          3. Having received oral bisphosphonate treatment for at least 2 years.

          4. Suboptimal response to bisphosphonate treatment, defined as either one of the
             following: (1) failure of lumbar spine, femoral neck or total hip BMD values to
             increase; (2) values of lumbar spine, femoral neck or total hip BMD remain
             osteoporotic, ie. T scores &lt; -2.5 or Z scores &lt; -2.0; or (3) development of new
             fragility vertebral or non-vertebral fractures despite at least 2 years' treatment
             with good compliance.

          5. Informed consent from patients.

        Exclusion Criteria:

          1. Patients with previous use of denosumab or teriparatide.

          2. Premenopausal women who plan for pregnancy within 2 years of study entry or who do not
             agree for contraception within this 2-year period.

          3. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and
             hyperparathyroidism.

          4. Patients with unexplained hypocalcemia.

          5. Patients with serum creatinine level of &gt;=200umol/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Chiu Mok, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuen Mun Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2011</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>denosumab</keyword>
  <keyword>RANKL</keyword>
  <keyword>glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

